Table 7.
Post-bevacizumab treatment
| Treatment | No. (%) | LD (n=33) | ED (n=5) | p-value |
|---|---|---|---|---|
| Surgical therapy | 1 (2.6) | 1 (3.0) | 0 | 0.358a) |
| Radiation therapy | 9 (23.7) | 9 (27.3) | 0 | - |
| Chemotherapy | 28 (73.7) | 23 (69.7) | 5 (100) | |
| Metronomic temozolomide | 10 (26.3) | 9 (27.3) | 1 (20.0) | 0.146b) |
| ACNU+CDDP | 8 (21.1) | 7 (21.2) | 1 (20.0) | |
| Bevacizumab re-introduction | 3 (7.9) | 1 (3.0) | 2 (40.0) | |
| Erlotinib | 4 (10.5) | 4 (12.1) | 0 | |
| PCV (procarbazine+CCNU+vincristine) | 3 (7.9) | 2 (6.1) | 1 (20.0) |
LD, late discontinuation; ED, early discontinuation.
a)
Calculated for treatment types (surgery, radiation therapy, and chemotherapy),
b)
Calculated for chemotherapy regimens.